FDA Grand Rounds: Assessing the Safety and Effectiveness of New and Emerging Therapeutic Ultrasound Technologies—Nov. 9, 2017

FDA Grand Rounds: Assessing the Safety and Effectiveness of New and Emerging Therapeutic Ultrasound Technologies—Nov. 9, 2017

Share this

Ultrasound’s long history as a medical tool dates back to the 1940s.  Today, diagnostic ultrasound’s ability to image in real-time, along with its excellent safety record and modern-day portability, has led to its prominence worldwide. 

FDA physicist Greg Clement, PhD, presents research into therapeutic ultrasound’s bioeffects, many of which remain poorly understood.  In recent years there has been a marked increase in the use of high-intensity ultrasound as a minimally invasive therapeutic tool.  Marketed devices now permit the treatment of certain cancers, uterine fibroids, and essential tremor, while investigations into treating many other brain disorders and various cancers are ongoing.

Presented by
Greg Clement, PhD
FDA’s Center for Devices and Radiological Health
Ultrasonics Laboratory

Thursday, November 9, 2017
12:00 pm to 1:00 pm
Register for the webcast here.

The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute presentation is followed by questions from the audience.

Stay up to date and subscribe to our blog

Latest blogs